11th Feb 2026 12:06
(Alliance News) - IP Group PLC on Wednesday said portfolio company Microbiotica Ltd has announced positive results from a phase 1b first-in-human trail of MB310 in ulcerative colitis patients.
The London-based investor in science and technology companies said Microbiotica is a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines.
IP Group has an undiluted beneficial holding of around 17% in Cambridge, England-based Microbiotica, valued at GBP13.9 million at the end of June.
Microbiotica noted that MB310 met its primary and secondary study objectives being safe and well tolerated, with successful engraftment of the MB310 bacteria.
It added that there were statistically significant improvements in efficacy parameters compared with placebo at the end of study assessments.
Clinical remission was achieved in 63% of MB310 treated patients compared to 30% in placebo treated patients.
Ulcerative colitis is an inflammatory bowel disease which affects over 1.4 million people globally.
"We are very excited about these promising results. MB310 has the potential to be a new, differentiated treatment modality for patients with ulcerative colitis, offering the hope of long-lasting disease remission without side effects.," said Microbiotica Chief Executive Officer Tim Sharpington.
"During 2026, we will explore partnering and financing options to determine the best route to fund our products through later studies and towards commercialisation."
Shares in IP Group were down 1.5% at 58.30 pence on Wednesday afternoon in London.
By Michael Hennessey, Alliance News reporter
Comments and questions to [email protected]
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Related Shares:
Ip Group